Finger-prick dried blood sampling can accurately measure key Alzheimer’s disease biomarkers, including p-tau217, GFAP, and ...

A technology that diagnoses various diseases, including Alzheimer’s and Parkinson’s, using just a few drops of blood from a ...

Measurements of phosphorylated tau 217 (p-tau217) in dried plasma spots (DPS) identified people with Alzheimer's disease ...

A new cellular balance test can detect a hidden inflammation in the brain, helping physicians to spot multiple sclerosis ...

Long before memory problems appear, your brain may already be losing neurons. That is the unsettling message from new work by ...

Artificial intelligence can use brain recordings from a single night in a sleep lab to predict a person's risk of developing ...

The government’s new vision for dementia diagnosis is ambitious: by 2029, more than 92 per cent of patients could receive a diagnosis within 18 weeks of referral, up from fewer than half today. Backed ...

HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical ...

Plasma measures of phosphorylated tau217 (p-tau217) can accurately identify individuals in the preclinical stage of Alzheimer’s disease (AD), a new meta-analysis showed. The results are important ...

Researchers are continuing to explore how the CXCL13-to-BAFF ratio can be used to advance precision medicine for people with multiple sclerosis.

Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.